Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Blood (2024) 144 (Supplement 1): 224.

https://doi.org/10.1182/blood-2024-201694

Published: 2024

Journal Articles

Regulation of the Transcriptional Repressor BACH2 Overcomes Tonic Signaling-Driven CAR T Cell Dysfunction

Tien-Ching Chang, Amanda Heard, John Warrington, Jack Landmann, Sadia Afrin, Jufang Chang, Mehmet Emrah Selli, Yu-Sung Hsu, Nathan Singh

Blood (2023) 142 (Supplement 1): 2065.

https://doi.org/10.1182/blood-2023-182133

Published: 2023

Journal Articles

Enhancing MHC-Independent T Cell Receptors Using Rational Protein Engineering

Jufang Chang, Jack Landmann, Yangdon Tenzin, John Warrington, Mehmet Emrah Selli, Tien-Ching Chang, Michael Slade, Deepesh Gupta, Nathan Singh

Blood (2023) 142 (Supplement 1): 354.

https://doi.org/10.1182/blood-2023-182154

Published: 2023

Journal Articles

Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction

Blood (2023) 141 (26): 3153–3165.

https://doi.org/10.1182/blood.2023020100

Published: 2023

Includes: Supplemental data

Journal Articles

Costimulatory Domains Direct Distinct Fates of CAR T Cell Dysfunction

Mehmet Emrah Selli, Jack Landmann, John Lattin, Amanda Heard, John Warrington, Helen Ha, Jufang Chang, Natalie Kingston, Graham Hogg, Mark Foster, Samantha Kersting-Schadek, Marina Terekhova, David DeNardo, Todd A. Fehniger, Maxim Artyomov, Nathan Singh

Blood (2022) 140 (Supplement 1): 2354–2355.

https://doi.org/10.1182/blood-2022-159687

Published: 2022

Journal Articles

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Blood (2022) 140 (Supplement 1): 1328–1331.

https://doi.org/10.1182/blood-2022-157829

Published: 2022

Journal Articles

Antigen Glycosylation Is a Central Regulator of CAR T Cell Efficacy

Amanda Heard, Mehmet Emrah Selli, John Lattin, Jack Landmann, Jufang Chang, Helen Ha, Balraj Doray, Marco Ruella, Saar Gill, Katharina E. Hayer, Matthew D. Weitzman, Abby M. Green, Regina Fluhrer, Nathan Singh

Blood (2021) 138 (Supplement 1): 1721.

https://doi.org/10.1182/blood-2021-146651

Published: 2021

Journal Articles

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Blood (2019) 134 (Supplement_1): 247.

https://doi.org/10.1182/blood-2019-131024

Published: 2019

Journal Articles

CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis

Nathan Singh, MD, Olga Shestova, PhD, Katharina Hayer, Albert Hong, Pranali Ravikumar, MS, Atushi Hoshino, MD PhD, Ophir Shalem, PhD, Matthew D. Weitzman, PhD, Carl H June, MD, Saar I. Gill, MDPhD, Marco Ruella, MD

Blood (2018) 132 (Supplement 1): 698.

https://doi.org/10.1182/blood-2018-99-117328

Published: 2018

Journal Articles

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Marco Ruella, MD, Shannon L Maude, MD PhD, Boris Engels, PhD, David M. Barrett, Noelle Frey, MD, Katherine T Marcucci, PhD, Olga Shestova, PhD, Nathan Singh, MD, Jessica Perazzelli, PhD, David A Christian, PhD, Dana Haagen, BS, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Jennifer Brogdon, PhD, Regina M Young, PhD, David L Porter, MD, Carl H June, MD, Stephan A Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 807.

https://doi.org/10.1182/blood.V130.Suppl_1.807.807

Published: 2017

Journal Articles

Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function

David M. Barrett, MD PhD, Nathan Singh, MD, Ted J. Hofmann, PhD, Zachary Gershenson, Stephan A. Grupp, MD PhD

Blood (2016) 128 (22): 654.

https://doi.org/10.1182/blood.V128.22.654.654

Published: 2016

NARROW

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Regulation of the Transcriptional Repressor BACH2 Overcomes Tonic Signaling-Driven CAR T Cell Dysfunction

Enhancing MHC-Independent T Cell Receptors Using Rational Protein Engineering

Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction

Costimulatory Domains Direct Distinct Fates of CAR T Cell Dysfunction

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Antigen Glycosylation Is a Central Regulator of CAR T Cell Efficacy

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only